Molecular Partners AG
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Molecular Partners AG now
Current reporting with the operating signal separated from the noise.
Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript
The story matters when it changes Molecular Partners AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
The story matters when it changes Molecular Partners AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Molecular Partners AG and Orano Med Advance Development of MP0726 Radio-DARPin Candidate for Ovarian Cancer Treatment
The story matters when it changes Molecular Partners AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Molecular Partners AG Announces Key Developments in Radio-DARPin Programs and Expansion of Partnership with Orano Med
The story matters when it changes Molecular Partners AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Molecular Partners AG (NASDAQ:MOLN) Q4 2022 Earnings Call Transcript
Investors are testing whether Molecular Partners AG’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Molecular Partners AG
The story matters when it changes Molecular Partners AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Molecular Partners AG Investigation: Robbins LLP is Investigating Molecular Partners AG (MOLN) on Behalf of Shareholders
Investors are testing whether Molecular Partners AG’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest MOLN filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Molecular Partners AG, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →